Publication date: Oct 08, 2024
The goal of this observational study is to learn about the role of the human gut microbiome in antidepressant treatment response in adolescents with Major Depressive Disorder (MDD). Specifically, the study aims to collect microbiota samples of adolescents treated with fluoxetine, over the span of 8-weeks, to: * determine the influence of the microbiome on the efficacy of fluoxetine to treat adolescent depression. * test whether the gut microbiome from different timepoints can predict ultimate success of fluoxetine * investigate the interaction of gut microbiome composition and pharmacogenetic metabolizer status on steady-state plasma concentrations of fluoxetine. Depression symptom severity will be evaluated upon enrollment and 6-weeks into antidepressant treatment.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Major Depressive Disorder |
| drug | DRUGBANK | Fluoxetine |
| disease | MESH | depression |
| drug | DRUGBANK | Spinosad |
| drug | DRUGBANK | Metformin |
| drug | DRUGBANK | Nicotine |